CN102202737B - 二取代的2,3-二氮杂萘hedgehog通路拮抗剂 - Google Patents

二取代的2,3-二氮杂萘hedgehog通路拮抗剂 Download PDF

Info

Publication number
CN102202737B
CN102202737B CN200980143394.3A CN200980143394A CN102202737B CN 102202737 B CN102202737 B CN 102202737B CN 200980143394 A CN200980143394 A CN 200980143394A CN 102202737 B CN102202737 B CN 102202737B
Authority
CN
China
Prior art keywords
compound
cancer
pharmacology
acceptable salt
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980143394.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102202737A (zh
Inventor
J·A·巴斯蒂安
P·A·希普斯金
D·J·萨尔
T·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41566219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102202737(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102202737A publication Critical patent/CN102202737A/zh
Application granted granted Critical
Publication of CN102202737B publication Critical patent/CN102202737B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200980143394.3A 2008-11-03 2009-10-22 二取代的2,3-二氮杂萘hedgehog通路拮抗剂 Expired - Fee Related CN102202737B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11070308P 2008-11-03 2008-11-03
US61/110703 2008-11-03
US61/110,703 2008-11-03
PCT/US2009/061573 WO2010062507A1 (en) 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists

Publications (2)

Publication Number Publication Date
CN102202737A CN102202737A (zh) 2011-09-28
CN102202737B true CN102202737B (zh) 2014-03-26

Family

ID=41566219

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980143394.3A Expired - Fee Related CN102202737B (zh) 2008-11-03 2009-10-22 二取代的2,3-二氮杂萘hedgehog通路拮抗剂

Country Status (29)

Country Link
US (1) US8404687B2 (cg-RX-API-DMAC10.html)
EP (1) EP2364185B1 (cg-RX-API-DMAC10.html)
JP (1) JP2012507535A (cg-RX-API-DMAC10.html)
KR (1) KR101335746B1 (cg-RX-API-DMAC10.html)
CN (1) CN102202737B (cg-RX-API-DMAC10.html)
AU (1) AU2009320251C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0921437A2 (cg-RX-API-DMAC10.html)
CA (1) CA2742539C (cg-RX-API-DMAC10.html)
CL (1) CL2011000979A1 (cg-RX-API-DMAC10.html)
CO (1) CO6382123A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110202A (cg-RX-API-DMAC10.html)
CY (1) CY1114023T1 (cg-RX-API-DMAC10.html)
DK (1) DK2364185T3 (cg-RX-API-DMAC10.html)
EA (1) EA018931B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011021A (cg-RX-API-DMAC10.html)
ES (1) ES2418479T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20130527T1 (cg-RX-API-DMAC10.html)
IL (1) IL211841A0 (cg-RX-API-DMAC10.html)
MA (1) MA32726B1 (cg-RX-API-DMAC10.html)
MX (1) MX2011004683A (cg-RX-API-DMAC10.html)
NZ (1) NZ591945A (cg-RX-API-DMAC10.html)
PE (1) PE20110433A1 (cg-RX-API-DMAC10.html)
PL (1) PL2364185T3 (cg-RX-API-DMAC10.html)
PT (1) PT2364185E (cg-RX-API-DMAC10.html)
SI (1) SI2364185T1 (cg-RX-API-DMAC10.html)
TN (1) TN2011000166A1 (cg-RX-API-DMAC10.html)
UA (1) UA102115C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010062507A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201102448B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA100684C2 (uk) * 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
US7981892B2 (en) 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8507490B2 (en) 2008-11-17 2013-08-13 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
WO2010056620A1 (en) 2008-11-17 2010-05-20 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
EP4229828A4 (en) 2020-10-13 2024-08-28 Endeavor Biomedicines, Inc. METHODS OF TREATMENT OF FIBROSIS
KR20250069659A (ko) * 2022-09-23 2025-05-19 머크 샤프 앤드 돔 엘엘씨 Nod-유사 수용체 단백질 3의 억제제로서 유용한 프탈라진 유도체
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2006028958A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2008110611A1 (en) * 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
NZ326354A (en) 1996-01-15 1999-05-28 Janssen Pharmaceutica Nv 3-(substituted-1-piperazinyl)-6-(substituted-1,2,4-thiadiazol-5 -yl)-pyridazine derivatives and medicaments
EP0882717B1 (en) * 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
IL138645A0 (en) 1998-04-09 2001-10-31 Univ Johns Hopkins Med Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
EP1183040B1 (en) 1999-06-08 2004-12-01 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog signalling pathway
US7655674B2 (en) 2002-04-22 2010-02-02 The Johns Hopkins University Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
JP5221952B2 (ja) 2004-05-08 2013-06-26 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド ３−アリール−５，６−ジ置換ピリダジン類
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
CA2697682A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inapropriate hedgehog signalling
US7981892B2 (en) 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8507490B2 (en) 2008-11-17 2013-08-13 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
WO2010056620A1 (en) 2008-11-17 2010-05-20 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2006028958A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2008110611A1 (en) * 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses

Also Published As

Publication number Publication date
US20110190304A1 (en) 2011-08-04
MX2011004683A (es) 2011-06-20
CN102202737A (zh) 2011-09-28
CA2742539A1 (en) 2010-06-03
CO6382123A2 (es) 2012-02-15
AU2009320251A1 (en) 2010-06-03
CL2011000979A1 (es) 2011-10-07
IL211841A0 (en) 2011-06-30
EA018931B1 (ru) 2013-11-29
PE20110433A1 (es) 2011-07-09
ZA201102448B (en) 2012-09-26
CY1114023T1 (el) 2016-07-27
US8404687B2 (en) 2013-03-26
AU2009320251B2 (en) 2013-01-24
ES2418479T3 (es) 2013-08-14
HK1159010A1 (en) 2012-07-27
WO2010062507A1 (en) 2010-06-03
NZ591945A (en) 2012-10-26
CA2742539C (en) 2014-05-06
BRPI0921437A2 (pt) 2018-10-30
EP2364185A1 (en) 2011-09-14
EA201170640A1 (ru) 2011-12-30
PT2364185E (pt) 2013-07-24
MA32726B1 (fr) 2011-10-02
JP2012507535A (ja) 2012-03-29
KR20110066212A (ko) 2011-06-16
UA102115C2 (ru) 2013-06-10
CR20110202A (es) 2011-06-09
HRP20130527T1 (en) 2013-07-31
KR101335746B1 (ko) 2013-12-12
SI2364185T1 (sl) 2013-07-31
TN2011000166A1 (en) 2012-12-17
DK2364185T3 (da) 2013-06-03
ECSP11011021A (es) 2011-06-30
PL2364185T3 (pl) 2013-10-31
AU2009320251C1 (en) 2013-08-15
EP2364185B1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
CN102202737B (zh) 二取代的2,3-二氮杂萘hedgehog通路拮抗剂
CN102459233B (zh) 二取代的酞嗪hedgehog途径拮抗剂
JP5518887B2 (ja) 四置換ピリダジンヘッジホッグ経路アンタゴニスト
KR101260116B1 (ko) 이치환된 프탈라진 헤지호그 경로 길항제
JP5518088B2 (ja) 四置換ピリダジンヘッジホッグ経路アンタゴニスト
HK1159010B (en) Disubstituted phthalazine hedgehog pathway antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140326

Termination date: 20141022

EXPY Termination of patent right or utility model